Nektar Therapeutics Reports Second Quarter 2022 Financial Results

SAN FRANCISCO, Aug. 4, 2022 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) today reported financial results for the second quarter ended June 30, 2022. Cash and investments in marketable securities at June 30, 2022, were approximately $628.2 million as compared to $798.8 million at...

Click to view original post